



PATENT

Case Docket No. TOYAM77.001AUS  
Date: April 5, 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Toshio Imai, et al.

Appl. No. : 09/963,316

Filed : September 25, 2001

For : USES OF ANTI-CX3CR1  
ANTIBODY, ANTI-  
FRACTALKINE ANTIBODY  
AND FRACTALKINE

Examiner : Unknown

Group Art Unit : Unknown

I hereby certify that this correspondence and all marked  
attachments are being deposited with the United States  
Postal Service as first class mail in an envelope addressed  
to: United States Patent and Trademark Office, P.O. Box  
2327, Arlington, VA 22202, on

April 5, 2002

(Date)

Katsuhiro Arai, Reg. No. 43,315

## TRANSMITTAL LETTER


United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

## ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with four (4) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Katsuhiro Arai  
Registration No. 43,315  
Agent of Record

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Imai, et al. ) Group Art Unit Unknown  
App. No. : 09/963,316 )  
Filed : September 25, 2001 )  
For : USES OF ANTI-CX3CR1 )  
ANTIBODY, ANTI- )  
FRACTALKINE ANTIBODY )  
AND FRACTALKINE )  
Examiner : Unknown )

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 5, 2002

By: 

Katsuhiro Arai  
Registration No. 43,315  
Agent of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(949) 760-0404

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TOYAM77.001AUS	APPLICATION NO. 09/963,316
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Toshio Imai, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE September 25, 2001	GROUP Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	2001-218581	08/14/01	Japan (Concise explanation of the relevance)			abstract	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
	2.	Toshio Imai, et al., Identification and Molecular Characterization of Fractalkine Receptor CX <sub>3</sub> CR1, which Mediates Both Leukocyte Migration and Adhesion, Cell, Vol. 91, 521-530, November 14, 1997	
	3.	Lili Feng, et al., Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX <sub>3</sub> CR1 <i>Rapid Communication</i>	
	4.	Proceedings of the Japanese Society for Immunology, Vol. 30, 2000, p.192; 2-F-270-PIO with an English translation	

H:\DOCS\KOAKOA-2383.DOC  
040502

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	